Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Therapeutics|August 18, 2015
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C LevelsEli M Roth, Maja Bujas-Bobanovic, Michael J Louie, et al.
The Journal of Continuing Education in the Health Professions|January 21, 2004
Short-term educational intervention improves family physicians' knowledge of depressionStanley Kutcher, Bianca Lauria-Horner, Connie MacLaren, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Evaluating the Impact of an Educational Program on Practice Patterns of Canadian Family Physicians Interested in Depression TreatmentStanley Paul Kutcher, Bianca Aurora Lauria-Horner, Connie Marian MacLaren, et al.
Canadian Family Physician Medecin De Famille Canadien|September 16, 2010
Game-based versus traditional case-based learning: comparing effectiveness in stroke continuing medical educationDeanna Telner, Maja Bujas-Bobanovic, David Chan, et al.
Diabetes, Obesity & Metabolism|February 17, 2017
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO IILawrence A Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, et al.
Atherosclerosis|July 31, 2018
Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trialMarja-Riitta Taskinen, Stefano Del Prato, Maja Bujas-Bobanovic, et al.
Diabetes, Obesity & Metabolism|March 2, 2018
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trialsRobert R Henry, Dirk Müller-Wieland, Pam R Taub, et al.
Diabetes, Obesity & Metabolism|May 27, 2018
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trialsOm P Ganda, Jorge Plutzky, Santosh K Sanganalmath, et al.
The Journal of Continuing Education in the Health Professions|March 17, 2009
Improved cardiovascular prevention using best CME practices: a randomized trialRéjean Laprise, Robert Thivierge, Gilbert Gosselin, et al.
The Journal of Clinical Endocrinology and Metabolism|June 6, 2019
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated StatinDirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, et al.
Pageof 2